Myriad Genetics (NASDAQ:MYGN) Stock Gets Price Target Bump from Leerink Partners

Myriad Genetics (NASDAQ:MYGN) had its target price increased by stock analysts at Leerink Partners from $5.00 to $8.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “market perform” rating on the stock. Leerink Partners‘s target price would indicate a potential upside of 35.14% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. TD Cowen raised their target price on shares of Myriad Genetics from $4.00 to $4.50 and gave the stock a “hold” rating in a research report on Tuesday, October 13th. Wells Fargo & Company set a $4.50 price objective on Myriad Genetics in a research note on Tuesday, October 20th. Stephens reduced their price objective on Myriad Genetics from $5.00 to $3.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 18th. Piper Sandler raised Myriad Genetics from an “underweight” rating to a “neutral” rating and set a $5.00 target price for the company in a research report on Tuesday, October 20th. Finally, UBS Group began coverage on Myriad Genetics in a report on Wednesday, September 9th. They issued a “neutral” rating and a $3.60 target price for the company. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $5.55.

Myriad Genetics Trading Down 5.9%

MYGN stock traded down $0.37 during midday trading on Thursday, reaching $5.92. The company’s stock had a trading volume of 2,562,310 shares, compared to its average volume of 3,077,596. Myriad Genetics has a 1 year low of $2.74 and a 1 year high of $8.09. The firm has a market capitalization of $566.25 million, a price-to-earnings ratio of -4.35 and a beta of 1.62. The stock has a fifty day simple moving average of $4.50 and a two-hundred day simple moving average of $4.62. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.21.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Wednesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.09. The firm had revenue of $202.70 million during the quarter, compared to analyst estimates of $191.33 million. Myriad Genetics had a negative net margin of 13.96% and a negative return on equity of 16.09%. On average, equities research analysts predict that Myriad Genetics will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Myriad Genetics

Several institutional investors have recently bought and sold shares of the business. Allworth Financial LP bought a new position in Myriad Genetics in the second quarter worth about $25,000. Pinnacle Associates Ltd. purchased a new stake in shares of Myriad Genetics during the third quarter valued at about $44,000. Integrated Wealth Concepts LLC bought a new stake in shares of Myriad Genetics in the 2nd quarter valued at about $54,000. Hsbc Holdings PLC bought a new stake in shares of Myriad Genetics in the 2nd quarter valued at about $61,000. Finally, E Fund Management Co. Ltd. purchased a new position in shares of Myriad Genetics in the 2nd quarter worth approximately $67,000. 99.02% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Myriad Genetics

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, above analysts’ $191.33 million estimate, and a loss of $0.11 per share—narrower than the expected $0.20 loss. The company also raised the midpoint of its FY2026 revenue outlook to a range of $780 million–$790 million. Article: Myriad Genetics Raises FY26 Revenue Outlook Midpoint
• Positive Sentiment: TD Cowen raised its price target to $6.75 from $4.50, while retaining a Hold rating; Leerink Partners raised its target to $8 from $5, with a Market Perform rating. Higher targets suggest improved expectations, though neither firm upgraded its rating. Article: TD Cowen price target
• Neutral Sentiment: Myriad agreed to sell its Prenatal Health business for $210 million. The proceeds could support the company’s finances and focus, but the divestiture also changes its revenue base; the outlook is presented following the sale. Article: Myriad outlines 2026 outlook following divestiture
• Negative Sentiment: The company said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential exposure of sensitive information or disruption creates uncertainty and could be contributing to investor concern. Article: Myriad reports cybersecurity incident

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.